Key result
Inhibition of the NLRP3 inflammasome with MCC950 reduced cardiac pyroptosis and fibrosis in a mouse model of viral myocarditis by decreasing CXCL4 production via the Wnt/β-Catenin and PI3K/AKT signaling pathways.
Why the study?
Severe myocarditis is often accompanied by cardiac fibrosis, but the exact mechanism by which inhibiting NLRP3 inflammasome-mediated pyroptosis reduces fibrosis remains unknown.
p-value: p=<0.05
CXCL4 promotes cardiac fibrosis in viral myocarditis via the PI3K/AKT pathway following NLRP3-mediated pyroptosis, highlighting it as a potential therapeutic target.
NLRP3 pyroptosis inhibition attenuates fibrosis in CVB3 myocarditis models; leaves open clinical translation in patients.
Severe myocarditis is often accompanied by cardiac fibrosis, but the underlying mechanism has not been fully elucidated. NOD-like receptor protein 3 (NLRP3) inflammation, closely related to apoptosis pyroptosis, participates in the development of myocarditis. Inhibiting pyroptosis mediated by NLRP3 inflammasome can reduce cardiac fibrosis, although its exact mechanism remains unknown. In this study, we induced Viral myocarditis (VMC) via infection of CVB3 to explore the relationship between pyroptosis and fibrosis. Our results showed that intraperitoneal injection of an NLRP3 inhibitor MCC950 or use of NLRP3−/−mice inhibited cardiac pyroptosis mediated by NLRP3 inflammasome in VMC. CXCL4 is a chemokine that has been reported to have pro-inflammatory and pro-fibrotic functions. In VMC, we further found that pyroptosis of Mouse myocardial fibroblasts (MCF) promoted the secretion of CXCL4 by activating Wnt/β-Catenin signaling. Subsequently, the transcriptome sequencing data showed that CXCL4 could promote cardiac fibrosis by activating PI3K/AKT pathway. In summary, infection of CVB3 induced host oxidative stress to further activate the NLRP3 inflammasome and ultimately lead to heart pyroptosis, in which MCF secreted CXCL4 by activating Wnt/β-Catenin signaling and CXCL4 participated in cardiac fibrosis by activating PI3K/AKT pathway. Therefore, our findings revealed the role of CXCL4 in VMC and unveiled its underlying mechanism. CXCL4 appears to be a potential target for the treatment of VMC.
No takes yet. Share an insight, caveat, or question.
Wei et al. (2023) studied Viral myocarditis and cardiac fibrosis. MCC950 (NLRP3 inhibitor) and LY294002 (PI3K inhibitor) vs. Vehicle/Control (VMC without treatment) was evaluated on Cardiac pyroptosis and fibrosis markers (p=<0.05). Inhibition of the NLRP3 inflammasome with MCC950 reduced cardiac pyroptosis and fibrosis in a mouse model of viral myocarditis by decreasing CXCL4 production via the Wnt/β-Catenin and PI3K/AKT signaling pathways.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: